ARTICLE | Clinical News

Rituxan rituximab: Phase II data; marketed to treat low-grade NHL

December 13, 1999 8:00 AM UTC

Phase II testing of Rituxan in combination with chemotherapy showed that the combination produced a 100 percent response rate in 35 evaluable low-grade NHL patients, with 22 complete responses and 13 partial responses. Median response duration was 39.7 months. Separately, the combination gave a 97 percent response rate in 33 intermediate or high-grade NHL patients, with 20 complete responses and 12 partial responses. After 24 months of follow-up, 27 evaluable patients had no evidence of progressive disease. Data were presented at the American Society of Hematology meeting in New Orleans. ...